AWP
AUPH icon

Abacus Wealth Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Abacus Wealth Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Sell
13,814
-10,785
-44% -$172K 0.02% 286
2026
Q1 		$365K Buy
24,599
+1,596
+7% +$23.3K 0.03% 296
2025
Q4 		$367K Buy
+23,003
New +$326K 0.04% 295

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abacus Wealth Partners's AUPH Position: Q2 2026 in Review

Abacus Wealth Partners reduced its Aurinia Pharmaceuticals (AUPH) stake by 44% in Q2 2026, selling an estimated $172K and leaving 13,814 shares worth $234K. The position accounts for 0.02% of the portfolio, ranked #286.

Abacus Wealth Partners first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $367K in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Abacus Wealth Partners held 13,814 shares of Aurinia Pharmaceuticals worth $234K as of Q2 2026.
  • Abacus Wealth Partners sold 10,785 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $172K.
  • Aurinia Pharmaceuticals made up 0.02% of Abacus Wealth Partners's portfolio in Q2 2026, its #286 holding.
  • Abacus Wealth Partners first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Abacus Wealth Partners's Aurinia Pharmaceuticals position peaked at $367K in Q4 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.